Total Payments
$74,850
2024 Payments
$24.53
Companies
25
Transactions
69
Medicare Patients
3,497
Medicare Billing
$1.6M
Payment Breakdown by Category
Research$73,029 (97.6%)
Food & Beverage$1,251 (1.7%)
Other$330.00 (0.4%)
Education$241.02 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $73,029 | 11 | 97.6% |
| Food and Beverage | $1,251 | 52 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $330.00 | 1 | 0.4% |
| Education | $241.02 | 5 | 0.3% |
Payments by Type
Research
$73,029
11 transactions
General
$1,822
58 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $57,816 | 6 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $7,774 | 1 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,163 | 4 | $0 (2019) |
| Acerta Pharma LLC | $2,941 | 2 | $0 (2019) |
| Eli Lilly and Company | $1,385 | 1 | $0 (2021) |
| PFIZER INC. | $508.03 | 14 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $197.60 | 11 | $0 (2023) |
| Astellas Pharma US Inc | $166.47 | 2 | $0 (2019) |
| Boston Scientific Corporation | $140.39 | 2 | $0 (2022) |
| GENZYME CORPORATION | $135.50 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24.53 | 1 | Eisai Inc. ($24.53) |
| 2023 | $220.16 | 10 | PFIZER INC. ($45.39) |
| 2022 | $364.09 | 15 | Boston Scientific Corporation ($140.39) |
| 2021 | $1,616 | 8 | Eli Lilly and Company ($1,385) |
| 2020 | $61.48 | 6 | PFIZER INC. ($19.94) |
| 2019 | $11,636 | 16 | Alexion Pharmaceuticals, Inc. ($7,774) |
| 2018 | $25,494 | 8 | Celgene Corporation ($22,570) |
| 2017 | $35,434 | 5 | Celgene Corporation ($35,195) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/05/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Oncology | ||||||
| 09/06/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/17/2023 | Amgen Inc. | Blincyto (Biological), Kyprolis | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Oncology | ||||||
| 08/01/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.19 | General |
| Category: Hematology | ||||||
| 07/28/2023 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $28.20 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Oncology | ||||||
| 06/21/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Oncology | ||||||
| 05/23/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $21.39 | General |
| 04/18/2023 | Epizyme, Inc. | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: Oncology | ||||||
| 03/31/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.79 | General |
| 01/03/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA, PAXLOVID | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/16/2022 | PFIZER INC. | BOSULIF (Drug), BESPONSA, PAXLOVID | Food and Beverage | In-kind items and services | $4.95 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/02/2022 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.45 | General |
| Category: Oncology | ||||||
| 09/26/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2022 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $21.57 | General |
| 09/11/2022 | PFIZER INC. | BOSULIF (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/06/2022 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: ONCOLOGY | ||||||
| 07/07/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.85 | General |
| Category: Oncology | ||||||
| 07/07/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $12.66 | General |
| Category: Hematology | ||||||
| 07/01/2022 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $15.87 | General |
| Category: Oncology | ||||||
| 06/16/2022 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: HEMATOLOGY | ||||||
| 04/05/2022 | Boston Scientific Corporation | SpyGlass (Device) | Food and Beverage | In-kind items and services | $89.86 | General |
| Category: SpyGlass_ENDO | ||||||
| 04/01/2022 | Boston Scientific Corporation | SpyGlass (Device) | Food and Beverage | In-kind items and services | $50.53 | General |
| Category: SpyGlass_ENDO | ||||||
| 03/14/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 | Celgene Corporation | $35,195 | 1 |
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $21,046 | 1 |
| PNH Registry | Alexion Pharmaceuticals, Inc. | $7,774 | 1 |
| The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT | Takeda Pharmaceuticals U.S.A., Inc. | $3,163 | 4 |
| A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | Acerta Pharma LLC | $2,941 | 2 |
| CC-122-DLBCL-001 - A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Celgene Corporation | $1,524 | 1 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $1,385 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 597 | 17,508 | $2.2M | $623,577 |
| 2022 | 38 | 1,008 | 12,645 | $930,588 | $260,967 |
| 2021 | 32 | 974 | 51,996 | $1.7M | $394,721 |
| 2020 | 33 | 918 | 39,428 | $1.6M | $341,213 |
Total Patients
3,497
Total Services
121,577
Medicare Billing
$1.6M
Procedure Codes
124
All Medicare Procedures & Services
124 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 16 | 12,240 | $1.5M | $459,772 | 29.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 2,520 | $164,400 | $46,373 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 326 | $75,306 | $31,086 | 41.3% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 12 | 12 | $43,260 | $14,477 | 33.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 145 | $33,640 | $14,417 | 42.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 29 | 99 | $67,914 | $10,590 | 15.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 41 | 78 | $25,350 | $10,558 | 41.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 135 | $27,675 | $7,954 | 28.7% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 15 | 15 | $18,000 | $6,206 | 34.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 86 | $14,448 | $5,548 | 38.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 33 | $13,596 | $4,780 | 35.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 60 | $18,240 | $2,997 | 16.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 31 | 225 | $23,625 | $2,765 | 11.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 16 | 35 | $2,450 | $2,607 | 106.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 37 | 90 | $8,370 | $1,014 | 12.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 14 | 41 | $6,232 | $949.14 | 15.2% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 640 | $72,960 | $569.70 | 0.8% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 14 | 18 | $4,320 | $554.94 | 12.8% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 11 | 17 | $1,547 | $244.95 | 15.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 19 | 635 | $635.00 | $62.19 | 9.8% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 19 | 58 | $406.00 | $50.29 | 12.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 12 | 2,940 | $175,800 | $50,891 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 159 | 438 | $100,940 | $42,839 | 42.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 58 | 206 | $65,060 | $30,483 | 46.9% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 16 | 18 | $64,890 | $22,375 | 34.5% |
About Leonard Klein
Leonard Klein is a Hematology & Oncology healthcare provider based in Niles, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1255328878.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Leonard Klein has received a total of $74,850 in payments from pharmaceutical and medical device companies, with $24.53 received in 2024. These payments were reported across 69 transactions from 25 companies. The most common payment nature is "" ($73,029).
As a Medicare-enrolled provider, Klein has provided services to 3,497 Medicare beneficiaries, totaling 121,577 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 124 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Niles, IL
- Active Since 09/29/2005
- Last Updated 12/17/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1255328878
Products in Payments
- Revlimid (Drug) $56,241
- SOLIRIS (Drug) $7,774
- CALQUENCE (Drug) $2,941
- CC-122 (Drug) $1,524
- IBRANCE (Drug) $374.12
- SpyGlass (Device) $140.39
- CYRAMZA (Drug) $125.95
- MOZOBIL (Drug) $116.65
- BOSULIF (Drug) $104.84
- FOUNDATIONONE (Device) $103.07
- SCEMBLIX (Drug) $77.53
- IMBRUVICA (Drug) $71.19
- CRESEMBA (Drug) $67.47
- Pomalyst (Drug) $51.20
- XARELTO (Drug) $50.57
- OPDIVO (Biological) $38.30
- TASIGNA (Drug) $36.05
- QINLOCK (Drug) $28.20
- MEKINIST (Drug) $24.96
- Defitelio (Drug) $24.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Niles
David Hakimian, Md, MD
Hematology & Oncology — Payments: $58,733
Hematology & Oncology $58,733
John Eklund, Md, MD
Hematology & Oncology — Payments: $18,589
Hematology & Oncology $18,589
Susan Brown, Md, MD
Hematology & Oncology — Payments: $7,601
Hematology & Oncology $7,601
Dr. Kristen Wendell, Do, DO
Hematology & Oncology — Payments: $3,747
Hematology & Oncology $3,747
Bruce Kaden, Md, MD
Hematology & Oncology — Payments: $86.84
Hematology & Oncology $86.84